Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for GlaxoSmithKline plc (GSK : NYSE)
 
 • Company Description   
Glaxo has 3 core businesses - Pharmaceuticals, Vaccines and Consumer Healthcare. The company has made significant progress in expanding its presence in emerging markets by acquiring product portfolios from companies like Bristol-Myers and UCB. In August 2019, Glaxo and Pfizer merged their consumer healthcare unit into a new JV. Glaxo owns a controlling stake in the JV. Glaxo plans to split itself into two standalone companies. The new Glaxo will be a biopharma company. Glaxo intends to separate its Consumer Healthcare segment into a standalone company in 2022. The independent Consumer Healthcare company will be named Haleon. In 2015, Glaxo divested two quadrivalent meningitis ACWY vaccines ' Nimenrix and Mencevax ' to Pfizer, a portfolio of OTC brands to Perrigo, and all its remaining rights to Arzerra for auto-immune indications including multiple sclerosis to Novartis. In January 2019, Glaxo acquired Tesaro, an oncology focused biotech company, which added the PARP inhibitor Zejula to its portfolio.

Number of Employees: 90,096

 
 • Price / Volume Information   
Yesterday's Closing Price: $44.52 Daily Weekly Monthly
20 Day Moving Average: 5,541,051 shares
Shares Outstanding: 2,541.79 (millions)
Market Capitalization: $113,160.72 (millions)
Beta: 0.64
52 Week High: $46.97
52 Week Low: $37.80
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.78% 8.64%
12 Week 4.31% 17.23%
Year To Date 0.95% 23.33%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
980 GREAT WEST ROAD
-
BRENTFORD,X0 TW8 9GS
GBR
ph: 44-20-8047-5000
fax: 44-20-8047-7807
gsk.investor-relations@gsk.com http://www.gsk.com
 
 • General Corporate Information   
Officers
Emma Walmsley - Chief Executive Officer
Jonathan Symonds - Chairman
Iain Mackay - Chief Financial Officer
Charles Bancroft - Director
Vindi Banga - Director

Peer Information
GlaxoSmithKline plc (AGN.)
GlaxoSmithKline plc (ABBV)
GlaxoSmithKline plc (NVO)
GlaxoSmithKline plc (LLY)
GlaxoSmithKline plc (RHHBY)
GlaxoSmithKline plc (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 37733W105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/27/22
Share - Related Items
Shares Outstanding: 2,541.79
Most Recent Split Date: 11.00 (2.00:1)
Beta: 0.64
Market Capitalization: $113,160.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 3.07%
Current Fiscal Quarter EPS Consensus Estimate: $0.68 Indicated Annual Dividend: $1.37
Current Fiscal Year EPS Consensus Estimate: $3.18 Payout Ratio: 0.71
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: 0.02
Estmated Long-Term EPS Growth Rate: 7.07% Last Dividend Paid: 05/19/2022 - $0.94
Next EPS Report Date: 07/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 13.99
Trailing 12 Months: 13.21
PEG Ratio: 1.98
Price Ratios
Price/Book: 3.73
Price/Cash Flow: 15.39
Price / Sales: 2.27
EPS Growth
vs. Year Ago Period: 39.68%
vs. Previous Quarter: 27.54%
Sales Growth
vs. Year Ago Period: 28.29%
vs. Previous Quarter: 2.16%
ROE
03/31/22 - 28.13
12/31/21 - 26.33
09/30/21 - 26.27
ROA
03/31/22 - 7.57
12/31/21 - 7.21
09/30/21 - 7.13
Current Ratio
03/31/22 - 1.19
12/31/21 - 0.79
09/30/21 - 0.81
Quick Ratio
03/31/22 - 0.95
12/31/21 - 0.54
09/30/21 - 0.54
Operating Margin
03/31/22 - 16.93
12/31/21 - 16.63
09/30/21 - 16.69
Net Margin
03/31/22 - 14.03
12/31/21 - 12.90
09/30/21 - 13.01
Pre-Tax Margin
03/31/22 - 17.83
12/31/21 - 15.95
09/30/21 - 16.93
Book Value
03/31/22 - 11.95
12/31/21 - 10.90
09/30/21 - 11.14
Inventory Turnover
03/31/22 - 2.09
12/31/21 - 1.88
09/30/21 - 1.80
Debt-to-Equity
03/31/22 - 1.29
12/31/21 - 0.96
09/30/21 - 0.95
Debt-to-Capital
03/31/22 - 56.36
12/31/21 - 49.08
09/30/21 - 48.81
 

Powered by Zacks Investment Research ©